PT  - JOURNAL ARTICLE
AU  - Marinkovic, Mladen
AU  - Stojanovic-Rundic, Suzana
AU  - Stanojevic, Aleksandra
AU  - Ostojic, Marija
AU  - Gavrilovic, Dusica
AU  - Jankovic, Radmila
AU  - Maksimovic, Natasa
AU  - Stroggilos, Rafael
AU  - Zoidakis, Jerome
AU  - Castellví-Bel, Sergi
AU  - Fijneman, Remond J.A.
AU  - Cavic, Milena
TI  - Exploring novel inflammation-related genetic and hematological predictors of response to neoadjuvant chemoradiotherapy in locally advanced rectal cancer
AID  - 10.1101/2023.06.20.23291673
DP  - 2023 Jan 01
TA  - medRxiv
PG  - 2023.06.20.23291673
4099  - http://medrxiv.org/content/early/2023/06/22/2023.06.20.23291673.short
4100  - http://medrxiv.org/content/early/2023/06/22/2023.06.20.23291673.full
AB  - Background The standard initial treatment for locally advanced rectal cancer (LARC) is neoadjuvant chemoradiotherapy (nCRT). In order to select patients who would benefit the most from nCRT, there is a strong need for predictive biomarkers. The aim of this study was to evaluate the role of clinical, pathological, radiological, inflammation-related genetic, and hematological parameters in the prediction of response after nCRT.Methods In silico analysis of published transcriptomics datasets was conducted to identify the best candidate genes, whose expression will be measured using quantitative Real Time PCR (qRT-PCR) in pretreatment formaline-fixed paraffin-embedded (FFPE) samples. In this study, 75 patients with LARC, between June 2020 and January 2022, were prospectively included. Patients were assessed for tumor response in the 8th week after nCRT completion with pelvic MRI scan and rigid proctoscopy. For patients with a clinical complete response (cCR) and initially distant located tumor no immediate surgery was suggested (“watch and wait” approach). The response after surgery was assessed using histopathological tumor regression grading (TRG) categories from postoperative specimens by Mandard. Responders (R) were defined as patients with cCR without operative treatment, and those with TRG 1 and TRG 2 postoperative categories. Non-responders (NR) were patients classified as TRG 3-5.Results Responders group comprised 35 patients (46.6%) and NR group included 53.4% of patients. Analysis of published transcriptomics data identified genes that could predict response to treatment and their significance was assessed in our cohort by qRT-PCR. When comparison was made in the subgroup of patients who were operated (TRG1 vs. TRG4), the expression of IDO1 was significantly deregulated (p<0.05). Among hematological parameters between R and NR a significant difference in the response was detected for neutrophil-to-monocyte ratio (NMR), initial basophil, eosinophil and monocyte counts (p<0.01). According to MRI findings, non-responders were more often presented with extramural vascular invasion (p<0.05).Conclusion Based on logistic regression model, factors associated with favorable response to nCRT were found to be tumor morphology as well as hematological parameters which can be easily and routinely derived from initial laboratory results (NMR, eosinophil, basophil and monocyte counts) in a minimally invasive manner. Using various metrics, an aggregated score of the initial eosinophil, basophil, and monocyte counts demonstrated the best predictive performance.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was funded by the Horizon Europe Project STEPUPIORS (Agreement No. 101079217) and the Ministry of Education and Science of the Republic of Serbia (Agreement No. 451-03-47/2023-01/200043).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study has been approved by the Ethics Committee of the Institute for Oncology and Radiology of Serbia and the Ethics Committee of the Faculty of Medicine, University of Belgrade, Serbia. All patients signed an informed consent. All experiments have been performed in accordance with the Helsinki Declaration of 1975, as revised in 2013.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesThe data that support the findings of this study are available upon reasonable request from the corresponding author. The data are not publicly available due to ethics restrictions as their containing information could compromise the privacy of patients.CRCcolorectal cancerLARClocally advanced rectal cancerMRImagnetic resonance imagingnCRTneoadjuvant chemoradiotherapypCRpathologic complete responsecCRclinical complete responseNCBI GEONational center for biotechnology information gene expression omnibusTRGtumor regression gradingGSEAgene set enrichment analysisKEGGKyoto encyclopedia of genes and genomesCTcomputed tomographyRTradiotherapyVMAT-SIBvolumetric modulated arc therapy-simultaneous integrated boost techniquePRpartial responseFFPEformaline-fixed paraffin-embeddedEDTAethylenediaminetetraacetic acidCBCcomplete blood countNLRneutrophil-to-lymphocyte ratioPLRplatelet-to-lymphocyte ratiodNLRderived neutrophil-to-lymphocyte ratioLMRlymphocyte-to-monocyte ratioPMRplatelet-to-monocyte ratioNMRneutrophil-to-monocyte ratioUICCUnion for International Cancer ControlECOGEastern cooperative oncology groupcDNAcomplementary DNAqRT-PCRquantitative Real Time PCRGAPDHglyceraldehyde-3-phosphate dehydrogenaseSDstandard deviationROCreceiver operating characteristics curveAUC ROCarea under the ROC curveAUCRPArea Under Precision-Recall CurveRMSERoot Mean Square ErrorEMVIextramural vascular invasionRFMDARandom Forest Mean Decrease in AccuracyDFSdisease-free survivalanti-PD-1 inhibitorprogrammed death 1 inhibitorMSImicrosatellite instabilitydMMRmismatch repair–deficient